APEX – Neuronal Nicotinic Receptors (NNRs) Present New Target for Treatment of Brain Disorders ABT-089 Now in National Trial to Test Benefits for Alzheimer’s Disease

APEX Reaserch Logo

Contact: Janet Henderson 828-883-4888

Neuronal Nicotinic Receptors (NNRs) Present New Target for Treatment of Brain Disorders ABT-089 Now in National Trial to Test Benefits for Alzheimer’s Disease

Santa Ana, CA Date 

Scientists are now targeting neuronal nicotinic receptors (NNRs), found on nerve cells throughout the central nervous system, for treatment of a number of neurological and psychiatric disorders.  Selective compounds have been developed to activate NNRs in order to stimulate the release of several important neurotransmitters which have been shown to improve cognition in laboratory studies.  The brain relies on these neurotransmitters (chemicals such as dopamine and acetylcholine), to enable nerve cells to communicate with one another.  Abbott researchers are now developing NNR compounds, including investigational medication ABT-089, for the potential treatment of Alzheimer’s disease.  

“At Abbott, we’ve been studying NNRs for more than a decade, and we are hopeful that this innovative research will lead to important advances in the treatment of cognitive disorders that disrupt the lives of patients and their families,” said Mario Saltarelli, M.D., Ph.D., divisional vice president, Neuroscience Development, Abbott. 

ABT-089 is now being evaluated for its safety and effectiveness in Alzheimer’s disease, a progressive and devastating brain disorder that destroys the capacity to remember, reason, communicate, and perform routine tasks.  In Alzheimer’s disease, nerve cells lose the ability to communicate with one another and eventually die.  Developed by Abbott, ABT-089 is designed to activate NNRs in the brain in an effort to restore proper chemical signaling in brain regions damaged by the disease.  Testing of the effects of ABT-089 on cognitive function in Alzheimer’s patients is currently underway.

“Clinical trials are crucial to finding new and better ways to treat and prevent Alzheimer’s disease.” said John Duffy, M.D., who has been the principal investigator in over 26 Alzheimer’s trials.  “The effects of Alzheimer’s disease can be devastating to patients and their families, and this study offers patients the opportunity to help evaluate the potential of ABT-089, an investigational medication being studied for this disease.”

Apex Research Institute is currently enrolling Alzheimer’s patients for a 12-week phase 2 study of ABT-089. The ideal study participant has been diagnosed with mild to moderate Alzheimer’s disease and has been on Alzheimer’s medication for at least three months. After the 12-week study, participants have the option to openly receive ABT-089 as part of a long-term extension study.  Families of people with Alzheimer’s disease are encouraged to visit www.thinkALZ.com or call (714) 881-4391 to contact the nearest participating clinic. There is no cost to the study participants or their families, and transportation can be arranged. 

Complimentary memory screenings are also available at this clinic location to evaluate anyone with concerns regarding memory loss or possible Alzheimer’s disease.

Apex Research Institute has successfully performed over 500 clinical trials (Phase I-IV), both in-patient and outpatient, since 1984. Research areas include cardiology, endocrinology, psychiatry, fibromyalgia and women’s health. Apex Research Institute, strives to: Advance the knowledge and understanding of common cardiovascular and general medical conditions. Increase the effectiveness of treatments of such conditions and bring the advancements of our clinical research into the mainstream of understanding and treatment.


Office Phone: 828.883.4888 | Mobile: 813.992.7758 | email: janet@henderson-inc.com
copyright © 2005 Janet Henderson | website by: Tricycle Studios